Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Collagran Ag is an advanced bioactive wound dressing that combines a bovine-derived collagen matrix with the antimicrobial properties of silver. The collagen component acts as a sacrificial substrate for matrix metalloproteinases (MMPs), which are often elevated in chronic wounds and can impede the healing process by degrading growth factors and the extracellular matrix. By modulating the wound environment and providing a structural scaffold, the collagen promotes fibroblast migration and tissue regeneration. The integrated silver provides broad-spectrum antimicrobial activity by releasing silver ions that disrupt bacterial cell membranes, respiratory chains, and DNA replication, thereby reducing bioburden and preventing infection. It is primarily indicated for the management of chronic and acute wounds, including pressure ulcers, diabetic foot ulcers, venous stasis ulcers, and surgical wounds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Collagran Ag.